Actrii proteins for the treatment of pulmonary arterial hypertension (pah)
AssigneeAcceleron Pharma Inc.
InventorsJanethe de Oliveira Pena, Peter Linde, Sachindra Joshi, Gang Li, Patrick Andre, Ravindra Kumar
Life of this patent
Estimating the term…
Abstract
In some aspects, the disclosure relates to compositions and methods comprising ActRII polypeptides to treat, prevent, or reduce the progression rate and/or severity of pulmonary arterial hypertension, particularly treating, preventing or reducing the progression rate and/or severity of one or more pulmonary arterial hypertension associated complications.
Claims31
1-212. (canceled)
A method of treating pulmonary arterial hypertension (PAH) in a patient in need thereof, comprising administering a therapeutically effective amount of an ActRIIA fusion protein comprising:
- a) an ActRIIA polypeptide comprising an amino acid sequence of SEQ ID NO:
- 2;
- b) an Fc domain comprising an amino acid sequence that is at least 95% identical to SEQ ID NO:
- 32;
- and
- c) a linker domain, positioned between the ActRIIA polypeptide and the Fc domain;
- wherein administration of the ActRIIA fusion protein results in one or more of the following:
- a) reduction of the risk of death by at least 50%;
- b) decrease of N-terminal pro B-type natriuretic peptide (NT-proBNP) levels by at least 400 μg/mL;
- c) reduction of the mean right atrial pressure (mRAP) in the patient by at least 10%;
- d) improvement in right ventricular function due to an increase in right ventricular fractional area change, a decrease in right ventricular hypertrophy, and/or an increase in ejection fraction;
- e) reduction in pulmonary vascular resistance (PVR) from baseline to 24 weeks by at least 1 Wood Unit;
- f) increase in 6-minute walk distance (6 MWD) from baseline to 24 weeks by at least 25 meters;
- or
- g) prevents or reduces pulmonary hypertension Functional Class progression as recognized by the World Health Organization (WHO).
A kit comprising a lyophilized polypeptide and an injection device, wherein the lyophilized polypeptide is an ActRIIA fusion protein comprising:
- a) an ActRIIA polypeptide comprising an amino acid sequence that is at least 90% identical to an amino acid sequence corresponding to residues 30-110 of SEQ ID NO:
- 1.
- b) an Fc domain of an IgG1 immunoglobulin;
- and
- c) a linker domain,
- wherein the linker domain is positioned between the ActRIIA polypeptide and the Fc domain of the IgG1 immunoglobulin,
- wherein the kit comprises one or more vials containing between 25 mg to 60 mg of the lyophilized ActRIIA fusion protein, citric acid monohydrate, tri-sodium citrate, polysorbate 80, and sucrose.
Dependencies are inferred from the claim text.